Comparing Healthcare Utilization and Cost in Empagliflozin versus GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease

被引：0
|
作者：
Htoo, Phyo T. [1 ,2 ]
Tesfaye, Helen [1 ]
DiCesare, Elyse C. [2 ,3 ]
Wexler, Deborah J. [4 ]
Schneeweiss, Sebastian [5 ]
Glynn, Robert [5 ]
Shay, Christina [6 ]
Schmedt, Niklas [6 ]
Koeneman, Lisette [6 ]
Paik, Julie M. [1 ]
Patorno, Elisabetta [1 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1285
引用
收藏
页码：580 / 580
页数：1
相关论文
共 50 条
  • [1] Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes
    Htoo, Phyo T.
    Tesfaye, Helen
    Wexler, Deborah J.
    Glynn, Robert
    Schmedt, Niklas
    Koeneman, Lisette
    Paik, Julie M.
    Patorno, Elisabetta
    DIABETES, 2024, 73
  • [2] Costs associated with healthcare resources utilization among empagliflozin versus GLP-1RA initiators in routine clinical care in Denmark
    Thomsen, Reimar
    Christensen, Lotte Brix
    Kahlert, Johnny
    Knudsen, Jakob
    Ustyugova, Anastasia
    Sandgaard, Susanne
    Holmgaard, Pia
    Ehlers, Lars
    Sorensen, Henrik Toft
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 36 - 36
  • [3] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Lars Holger Ehlers
    Mark Lamotte
    Sofia Monteiro
    Susanne Sandgaard
    Pia Holmgaard
    Evan C. Frary
    Niels Ejskjaer
    Diabetes Therapy, 2021, 12 : 1523 - 1534
  • [4] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Ehlers, Lars Holger
    Lamotte, Mark
    Monteiro, Sofia
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    DIABETES THERAPY, 2021, 12 (05) : 1523 - 1534
  • [5] Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
    Mishriky, Basem M.
    Cummings, Doyle M.
    Powell, James R.
    PRIMARY CARE DIABETES, 2022, 16 (03) : 471 - 473
  • [6] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [7] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Mafalda Ramos
    Peng Men
    Xu Wang
    Anastasia Ustyugova
    Mark Lamotte
    Cost Effectiveness and Resource Allocation, 19
  • [8] Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Gandhi, Pranav K.
    Cragin, Lael
    Brand, Sarah B.
    Pfarr, Egon
    Fahrbach, Kyle
    Ustyugova, Anastasia
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [9] Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study
    Tesfaye, Helen
    Paik, Julie M.
    Zakoul, Heidi
    Schmedt, Niklas
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES OBESITY & METABOLISM, 2025,
  • [10] Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
    Dave, Chintan V.
    Kim, Seoyoung C.
    Goldfine, Allison B.
    Glynn, Robert J.
    Tong, Angela
    Patorno, Elisabetta
    CIRCULATION, 2021, 143 (08) : 770 - 779
12345